Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61186/rbmb
en
jalali
1398
10
1
gregorian
2020
1
1
8
4
online
1
fulltext
en
Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells
زیست شناسی ملکولی
Molecular Biology
مقالات اصلی
Original Article
<strong><em>Background:</em></strong> Thyroid cancer is the most prevalent endocrine malignancies globally. Anaplastic thyroid carcinoma (ATC) accounts for 1-3% of all Thyroid cancer. The evidence showed that ATC is a highly invasive solid tumor with poor prognosis. Despite conventional chemotherapy treatments, a considerable number of patients show developing resistance to therapeutic agents and tumor relapse. The aim of this study was the investigation anti-tumor effect of Abemaciclib (novel targeted cancer therapy drug) on Anaplastic Thyroid carcinoma SW1736 and C643 cell lines.<br>
<br>
<em><strong>Methods: </strong></em>SW1736 and C643 cell lines were treated by desire concentrations of Abemaciclib (0, 1, 2.5, 5, 10, and 20 μM) and cell viability was measured by MTT assay. Also, Anoikis resistance assay was conducted for non-adherent the cells in the exposure of Abemaciclib. The gene expression of apoptotic and anti-apoptotic genes was conducted by quantitative Real-time PCR.<br>
<br>
<strong><em>Results:</em></strong> Abemaciclib at the concentration of 10 and 20 μM effectively reduced cell proliferation and growth of the ATC cells compared to the control (p=0.000). Furthermore, we showed that 10 and 20 μM doses of the Abemaciclib inhibited the non-adherent ATC cells which were resistant to Anoikis death significantly (p=0.001). Moreover, we demonstrated this targeted therapy significantly reduced anti-apoptotic gene expression levels (BCL2 and CMYC) (p<0.05) and increased apoptotic gene expressions such as P21 and BAX (p<0.05).<br>
<br>
<strong><em>Conclusions: </em></strong>Our data suggested that Abemaciclib can be utilized as a novel therapeutic agent in ATC cancer. Further in vivo and in vitro investigations are needed to evaluate molecular and clinical mechanisms of Abemaciclib.
Abemaciclib, Anaplastic Thyroid Carcinoma, CDK4/6 inhibitor.
438
445
http://rbmb.net/browse.php?a_code=A-10-351-1&slc_lang=en&sid=1
Elaheh Seyed
Abutorabi
10031947532846006802
10031947532846006802
Yes
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Shiva
Irani
10031947532846006803
10031947532846006803
No
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Marjan
Yaghmaie
10031947532846006804
10031947532846006804
No
Hematology/Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Hamid
Ghaffari
shghaffari_200@yahoo.com
10031947532846006805
10031947532846006805
No
Hematology/Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.